S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

$15.20
+0.04 (+0.26%)
(As of 03/27/2024 ET)
Today's Range
$15.11
$15.58
50-Day Range
$14.06
$16.79
52-Week Range
$11.03
$21.22
Volume
787,191 shs
Average Volume
806,081 shs
Market Capitalization
$1.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.22

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
26.5% Upside
$19.22 Price Target
Short Interest
Bearish
5.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of NeoGenomics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$38,702 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to ($0.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.88 out of 5 stars

Medical Sector

424th out of 939 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

NEO Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NeoGenomics Inc.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NEO Mar 2024 10.000 put
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Q4 2023 Neogenomics Inc Earnings Call
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
Recap: NeoGenomics Q4 Earnings
NeoGenomics: Q4 Earnings Snapshot
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Testing laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$19.22
High Stock Price Target
$24.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+26.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-87,970,000.00
Pretax Margin
-16.41%

Debt

Sales & Book Value

Annual Sales
$591.64 million
Cash Flow
$0.29 per share
Book Value
$7.39 per share

Miscellaneous

Free Float
125,951,000
Market Cap
$1.94 billion
Optionable
Optionable
Beta
1.10

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 61)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 58)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Warren Stone (Age 51)
    President of Clinical Division
    Comp: $722.79k
  • Gregory D. Aunan
    Senior VP & Chief Accounting Officer
  • Ms. Kendra Sweeney
    Vice President of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 40)
    General Counsel & Corporate Secretary
  • Mr. Hutan Hashemi J.D. (Age 45)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer
  • Ms. Melody Harris Esq. (Age 58)
    J.D., President of Enterprise Operations
  • Mr. Gary Passman
    Chief Culture Officer

NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price target for 2024?

11 Wall Street analysts have issued twelve-month price objectives for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $24.00. On average, they predict the company's share price to reach $19.22 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2024?

NeoGenomics' stock was trading at $16.18 at the beginning of the year. Since then, NEO shares have decreased by 6.1% and is now trading at $15.20.
View the best growth stocks for 2024 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its earnings results on Tuesday, February, 20th. The medical research company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The medical research company had revenue of $155.55 million for the quarter, compared to analyst estimates of $152.90 million. NeoGenomics had a negative trailing twelve-month return on equity of 4.13% and a negative net margin of 14.87%.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.12%), Vanguard Group Inc. (11.10%), Brown Advisory Inc. (7.57%), First Light Asset Management LLC (3.08%), Dimensional Fund Advisors LP (2.36%) and Schroder Investment Management Group (1.95%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
This page (NASDAQ:NEO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners